Coherus Oncology, Inc. (NASDAQ:CHRS – Free Report) – Analysts at HC Wainwright decreased their Q3 2026 earnings per share estimates for Coherus Oncology in a report issued on Thursday, August 6th. HC Wainwright analyst D. Tsao now forecasts that the biotechnology company will earn ($0.23) per share for the quarter, down from their previous forecast of ($0.18). The consensus estimate for Coherus Oncology’s current full-year earnings is ($0.88) per share. HC Wainwright also issued estimates for Coherus Oncology’s Q4 2026 earnings at ($0.21) EPS, FY2026 earnings at ($0.92) EPS, FY2027 earnings at ($0.68) EPS, FY2028 earnings at ($0.96) EPS, FY2029 earnings at ($0.79) EPS and FY2030 earnings at $0.12 EPS.
Other equities research analysts have also recently issued research reports about the stock. Guggenheim started coverage on shares of Coherus Oncology in a research report on Monday, May 11th. They set a “buy” rating and a $12.00 price target for the company. Weiss Ratings reissued a “hold (c)” rating on shares of Coherus Oncology in a research note on Friday, August 7th. Three investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $8.67.
Coherus Oncology Stock Performance
Coherus Oncology stock opened at $1.34 on Monday. The company has a current ratio of 1.77, a quick ratio of 1.70 and a debt-to-equity ratio of 0.61. Coherus Oncology has a 1 year low of $1.05 and a 1 year high of $2.62. The company has a market cap of $207.03 million, a PE ratio of -1.30 and a beta of 0.98. The company’s 50-day moving average is $1.42 and its two-hundred day moving average is $1.63.
Coherus Oncology (NASDAQ:CHRS – Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported ($0.19) EPS for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.06. The firm had revenue of $14.31 million during the quarter, compared to analyst estimates of $14.41 million. Coherus Oncology had a negative return on equity of 222.75% and a negative net margin of 259.41%.
Hedge Funds Weigh In On Coherus Oncology
Several institutional investors have recently modified their holdings of CHRS. Acadian Asset Management LLC raised its position in shares of Coherus Oncology by 52,980.1% in the 1st quarter. Acadian Asset Management LLC now owns 196,927 shares of the biotechnology company’s stock valued at $158,000 after acquiring an additional 196,556 shares during the period. Geode Capital Management LLC grew its holdings in Coherus Oncology by 0.8% during the second quarter. Geode Capital Management LLC now owns 2,676,476 shares of the biotechnology company’s stock valued at $1,958,000 after purchasing an additional 20,976 shares during the period. XTX Topco Ltd grew its holdings in Coherus Oncology by 65.3% during the second quarter. XTX Topco Ltd now owns 91,739 shares of the biotechnology company’s stock valued at $67,000 after purchasing an additional 36,257 shares during the period. Invesco Ltd. grew its holdings in Coherus Oncology by 11.5% during the second quarter. Invesco Ltd. now owns 208,271 shares of the biotechnology company’s stock valued at $152,000 after purchasing an additional 21,550 shares during the period. Finally, Jane Street Group LLC bought a new stake in Coherus Oncology in the second quarter valued at approximately $46,000. 72.82% of the stock is currently owned by institutional investors and hedge funds.
About Coherus Oncology
Coherus Oncology, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacturing and commercialization of biologic therapies for oncology support and immuno-oncology. Founded in 2010 and headquartered in Redwood City, California, Coherus specializes in biosimilar versions of established oncology agents as well as novel immunotherapy candidates.
The company’s lead marketed products include Udenyca (pegfilgrastim-cbqv) and Fulphila (pegfilgrastim-jmdb), biosimilars to Amgen’s Neulasta, which are designed to reduce the incidence of infection in patients undergoing myelosuppressive chemotherapy.
Recommended Stories
- Five stocks we like better than Coherus Oncology
- The AI Boom Is Turning This Cable Maker Into a Stock to Watch
- A Star Investor Just Trimmed Amazon—Here’s What It means
- Wendy’s Deal Buzz May Give Fast-Food Investors a New Reason to Look
- Home Depot Analysts See a Path to $375 and Beyond
Receive News & Ratings for Coherus Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
